AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the…
26,855€
-0,15%
Echtzeit-Aktienkurs DAIICHI SANKYO CO. LTD
Bid:
Ask:
Nachrichten zur DAIICHI SANKYO CO. LTD Aktie
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal
Merck & Co. won’t continue with two drug candidates it previously agreed to co-develop with a Chinese biotech after clinching…
Daiichi Sankyo to close Japanese research and development subsidiary
The subsidiary, Daiichi Sankyo RD Novare (RD Novare), with nearly 400 employees was initially named as Daiichi Sankyo RD Associe…
Daiichi Sankyo GAAP EPS of ¥29.72, revenue of ¥350.84B
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Daiichi Sankyo granted FDA approval for leukemia therapy Vanflyta
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
ALI HEALTH Notches Strategic Alliance with Daiichi Sankyo
ALI HEALTH (00241.HK) announced that it has recently established a strategic partnership with the e-commerce platform Daiichi Sankyo. Building on…
Dato-DXd significantly improved PFS in lung cancer
This announcement contains inside information
3 July 2023
Datopotamab deruxtecan met dual primary endpoint of
progression-free survival in patients with advanced
non-small cell lung…
AstraZeneca and Daiichi Sankyo report progress in cancer drug trials
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Daiichi Sankyo Co. GAAP EPS of ¥56.91, revenue of ¥1.28T
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Daiichi Sankyo FY22 Profit Rises; Revenue Up 22.4%
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF.PK) reported that its fiscal 2022 profit attributable to owners of the company…
Daiichi Sankyo leukemia candidate review extended three months by FDA
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Daiichi Sankyo, Confo ink deal to develop CNS treatments
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Daiichi Sankyo receives approval for ENHERTU in Japan
ENHERTU, which is a HER2 directed ADC, features a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload through…
Zymeworks and Daiichi Sankyo end bispecific antibody deal
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion (ESPR) Plummets 54% Over Milestone Payment Row
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the companys assessment that cardiovascular outcome CLEAR…
Esperion extends selloff as Daiichi Sankyo dispute prompts BofA downgrade
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Esperion Therapeutics falls 55% in dustup with Daiichi Sankyo over milestone payments
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
AstraZeneca (AZN) Enhertu Betters Outcomes in Multi-Tumor Study
AstraZeneca (AZN) and Daiichi Sankyo Enhertu met the pre-specified criteria for objective response rate and duration of response in the…
Astrazeneca meldet positive Ergebnisse für Krebsmittel Enhertu
Von Elena Vardon LONDON (Dow Jones)--Der Pharmakonzern Astrazeneca hat vielversprechende Ergebnisse für sein Krebsmedikament Enhertu zur Behandlung von Brustkrebs…
AstraZeneca: Enhertu DESTINY-PanTumor02 Shows Positive Results
LONDON (dpa-AFX) - British drug maker AstraZeneca Plc (AZN, AZN.L) and Daiichi Sankyo (DSKYF.PK) announced Monday that Enhertu (trastuzumab deruxtecan)…
Enhertu DESTINY-PanTumor02 shows positive results
06 March 2023 07:00 GMT
Enhertu showed clinically meaningful and durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial
AstraZeneca and…
Daiichi Sankyo: U.S. Patent Office Re-Institutes Post Grant Review Of Seagen Patent
TOKYO (dpa-AFX) - Daiichi Sankyo Co., Ltd. (DSKYF.PK) said that the U.S. Patent and Trademark Office granted its request to…
Daiichi Sankyo GAAP EPS of ¥45.19, revenue of ¥948.28B
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Daiichi Sankyo Applies for COVID-19 Vaccine Approval
Tokyo, Jan. 13 (Jiji Press)--Daiichi Sankyo Co. said Friday it has applied for health ministry approval for a COVID-19…
Daiichi Sankyo seeks marketing approval for mRNA Covid-19 vaccine DS-5670 in Japan
DS-5670 is an mRNA vaccine being developed against the novel coronavirus infectious disease (COVID-19). It is proposed to be used…
Daiichi Sankyo files for Japanese approval of mRNA COVID vaccine as booster
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Japan’s Daiichi Sankyo applies for approval of mRNA COVID vaccine
An approval would give Japan a homegrown mRNA vaccine — a vaccine type that has played a dominant role in…